U.S. markets closed

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
65.73+4.77 (+7.82%)
At close: 04:00PM EDT
65.63 -0.10 (-0.15%)
After hours: 07:27PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • B
    Growth is taking a hit because speculators believe borrowing cost will keep going up because of the new spending bill. I do not think most of the Crispr companies are in that much trouble. Although I am not sure how Medicare being able to negotiate prices will affect Crispr cures. I am still excited about the coming cures for genetic diseases.
  • A
    Looks like Ark had inside information. Not a coincidence that they sold before this news.
  • M
    Beam will be employing 525 people by the end of the year. Beam will snowball and no one is stopping us:

    "Erik Rocheford, a managing director at The Bowdoin Group, a Waltham-based executive search firm, said he's worked with a number of people impacted by layoffs who are already being widely courted. "The reality of being a candidate in this job market is you can be inundated with new opportunities,” Rocheford said.

    Susan O’Connor, the chief human resources officer at Beam Therapeutics Inc. (Nasdaq: BEAM), has fielded multiple requests from contemporaries about placing laid-off workers at the gene-editing company. O’Connor and her team have been able to use those leads to grow the company this year: Beam today employs about 485 people, up more than 40% since the end of 2021.

    “We’ve been the beneficiary of companies that have not fared well in the market,” O’Connor said. “Based on the network and our relationships with our biotech family, per se, when we know something’s happening, we get a phone call. Someone will say, ‘We might have to jettison people. Is there an opportunity at Beam?’”

    O’Connor is now overseeing a significant hiring push. In June, Beam received $2.1 million through the state and Massachusetts Life Sciences Center’s tax incentive program in exchange for adding 140 new positions at its headquarters in Cambridge. O’Connor says the company has already met that goal and will likely surpass it by September, and will employ somewhere between 515 and 525 people by the end of the year, most of them in Massachusetts."
    Faced with conflicting signs from all sides of the biotech economy, executives are left sorting out how to plan for growth.
    Faced with conflicting signs from all sides of the biotech economy, executives are left sorting out how to plan for growth.
  • R
    "Beyond BEAM-201, Beam is focused on identifying the collection of multiplex base edits required to make cells fully allogeneic, with internal and external data suggesting a higher number of edits will be required to meet this goal. As a result, Beam does not expect to nominate a second CAR-T development candidate in 2022 and anticipates providing further updates in 2023"

    Allo vs IPSC- they want to possibly concentrate on durability.
  • B
    What a difference a day makes. Growth back in.
  • R

    $BEAM clinical hold possibly due to miscommunication before IND submission, not safety findings. Could just be regulatory growing pain for inexperienced company.
  • J
    When is earnings call?
  • R
    Today is Synthetic Bio day in biotech with TWST earnings on Friday.
  • R
    Wei Zhao
    Relavant FDA IND status for BEAM-201
    BEAM-201: allo CD7 CAR-T; CD7, TCR, CD52, PD1 KO by CBE; on clinical hold
    BEAM-101: ex vivo ABE, IND clearance
    VERVE-101: in vivo ABE, to submit IND in 2H22
    WU-CART-007: allo CD7 CAR-T; CD7, TCR KO by CRISPR/Cas9, IND clearance
  • H
    This is not a big deal
  • K
    IND on clinical hold. Dead money for next 30 days at least.
  • R
    BEAM/VERV deal:
    Opt out: they get low to mid single digit royalties
    Opt in: share up to 35% of costs and get 35% of world wide sales.
    gets access to GalNac guided LNP delivery to the liver.
    pay VERV a low single digit royalty on any product using the GalNac LNP.
  • l
    NTLA will move BEAM HIGHER
  • i
    David R. Liu
    Today we report in
    the development of a suite of adenine based editors (ABEs) that are small enough to each fit, together with a guide RNA & all needed regulatory elements, into a single AAV to support efficient base editing in animals. 1/4
    Davis_Efficient in vivo base editing via single adenoassociated viruses with size-optimized genomes encoding compact adenine base editors.pdf
  • i
    FYI: All three of these gene editing companies reached new all-time highs in regards to shares held short. $BEAM 13,237,465, up 500,000+ shares, $EDIT 16,377,142, up 1,000,000+ shares, and $VERV 9,923,155, up 500,000+ shares.
  • R
    cells. Compared with other procedures for editing human cells, PE offers
    greater precision and versatility, and can be completed within 2–4 weeks.
    David Liu continues!
  • T
    The reality we are dealing with is simple. This is new… never done before science…. So you have to ask yourself if you think the science will prevail. Like the electric car, when it first came on the scene I’m sure there were people like F that thought that Tesla would not get much traction and that people would not migrate towards these types of vehicles, and you know that might have been true when fast was less than 2 dollars a gallon, but now that the price has jumped to where it is, and the price of these vehicles have come down… that shift is here to stay. Technology has a way of moving forward because humans are moving forward… this isn’t a drug that reacts differently with different people… this is something more profound than that, they are using the mechanism by which our bodies work… if the science proves out.. this will be a game changer..
  • R
    AI to increase depth of genome sequencing - from David Liu and his team:

    In vitro selection queries large combinatorial libraries for sequence-defined
    polymers with target binding and reaction catalysis activity. While the total
    sequence space of these libraries can extend beyond 1022 sequences, practical

    considerations limit starting sequences to ≤~1015 distinct molecules. Selection-
    induced sequence convergence and limited sequencing depth further con-
    strain experimentally observable sequence space. To address these limita-
    tions, we integrate experimental and machine learning approaches to explore

    regions of sequence space unrelated to experimentally derived variants. We
    perform in vitro selections to discover highly side-chain-functionalized nucleic
    acid polymers (HFNAPs) with potent affinities for a target small molecule

    (daunomycin KD = 5–65 nM).

    enables direct generation of active variants, demonstrating a new approach to
    the discovery of functional biopolymers.
  • R
    The FDA has recently paused testing of a number of gene replacement or gene editing therapies, wary of potential safety concerns.

    I own BEAM for BE and not for its CAR-T. The market doest care much about the hold after initial reaction. IND for BEAM 201 filed in June, 2022.
    Receiving a clinical hold on an asset that hasn't even started clinical trials is not really news

    How many 4-edit candidates already got IND so far?
    Several 3-edits. However risks of genetic rearrangements not linear at all with nb of edit, so where is the bar, what are the methods the FDA rely on to assess them in cGMP environment?
    FATE FT576 and FT538 both with 4 edits (including more complicated gain of function edits). Both have cleared IND, 576 has been dosing.
    iPSC product consistency showing its worth. From a reg perspective this is a huge advantage.
    GOF mutations/insertions don’t count? BEAM proprietary platform doesn’t even allow for insertions so they have to use other means.
    By these standards, all approved CAR-Ts wouldn’t count as edited cells either ?
    When a gene insertion liek with lenti is not performed at a target location, even if the insertions may end to be distributed at preferential sites,
    these are referred to as gene edits, at least not commonly,
    lenti is a backbone in CAR-Ts/NKs, so it's more the addition of multiple edits on top of that backbone that is likely underscrutiny here. At least that's what would be consistent with the freedback of other players in that field, when talking about performing multiplex edits in high nb.